I would like to comment briefly on the issue raised by Dr. Wheeler (1) with reference to the review by Tisdale (2) on the use of hydrazine sulfate for the treatment of patients with cancer cachexia.
The point, in my opinion, is not whether or not hydrazine sulfate was effective in the clinical trials reported by the authors but whether its use in that context was appropriate. We know, in fact, that 1) cancer patients have an increased glucose synthesis from lactate, alanine, and glycerol and 2) energy metabolism of human cancer cells mainly relies on glucose (3) (4) (5) (6) . Hydrazine sulfate is a gluconeogenic blocking agent that selectively starves tumor cells by interrupting the cycle of tumor energy gain and host energy deprivation at the enzymatic level of phosphoenol pyruvate-carboxykinase, thus preventing glucose formation from lactate and amino acids.
It seems obvious that if patients have a regular diet (as in the reported clinical trials), the intake of glucose with the diet is enough to maintain the energy metabolism of the cancer cells and to decrease or at least partially compensate the host for the shift of energy from the host tissue to the cancer cells due to the increased gluconeogenesis.
It is not surprising that, in such conditions, hydrazine sulfate proved to be ineffective. The efficacy of hydrazine sulfate should be tested when patients are given a complete but otherwise glucose-free diet (consequently, tumor energy metabolism is only supported by the endogenous production of glucose).
This nutritional approach may be taken because the brain, which is the main consumer of glucose (110-145 g/24 hours) switches to ketone body utilization after a short period of starvation. Moreover, the brain is able to directly use glycerol, whereas the tumor tissue cannot due to the very low activity of glycerokinase.
This approach is the hypothesis that we are currently testing, with good preliminary results with respect to tolerance and feasibility of an intravenous complete glucose-free nutritional regimen plus hydrazine sulfate (7). In his reply to my letter in a recent issue of the Journal (1) stressing the incompatibility of tranquilizers with monoamine oxidase (MAO) inhibitors in the National Cancer Institute (NCI)-sponsored studies of hydrazine sulfate, Dr. Wheeler states that there is considerable evidence that use of these medications (tranquilizers) was "inconsequential," since "the addition of medications that could potentially interact with MAO inhibitors in some patients did not statistically increase toxicity." This statement derives, at least in part, from NCI's retrospective statistical analyses of the largest of its hydrazine sulfate studies, containing a series of nine survival analysis figures, as submitted by the Cancer and Leukemia Group B to the U.S. General Accounting Office (2). These retrospective analyses and their underlying statistics were submitted to senior consultant biostatistician R JOSEPH GOLD ent context from that used in the three previous randomized trials ( [2] [3] [4] , there is no evidence as yet that this possibility is true. In the context that it was used, hydrazine showed no benefit. If the final results of Dr. Bozzetti's current trial turn out to be as good as his preliminary results suggest, perhaps these results would encourage interest in further studies. Any treatment that truly benefits cancer patients is welcome. However, once a treatment has clearly been shown not to work, its lack of efficacy should be accepted and its continued use should not be proposed unless new clinical evidence becomes available. On the basis of what we now know, there is no justification for another randomized trial with the use of hydrazine when much more promising clinical ideas are competing for scarce research funds.
FEDERICO BOZZETTI
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As to Dr. Gold's letter, I cannot comment on his statistical assertions because I could not review his references from letters sent to the U.S. General Accounting Office (GAO) or the article from Penthouse magazine. However, the GAO report that resulted from his allegations entitled "Cancer drug research: contrary to allegation, NIH hydrazine sulfate studies were not flawed" (5) is available. Dr. Gold's basic assertion has been that the studies were flawed because of the concurrent use of tranquilizers, barbiturates, and/or alcohol with hydrazine. The GAO report noted that there was controversy over whether his concerns about incompatibility had been scientifically validated in humans. The National Cancer Institute (NCI) and researchers from the Cancer and Leukemia Group B and the North Central Cancer Treatment Group (NCCTG) reviewed the same (mostly) preclinical reviewed by Dr. Gold and concluded the following: 1) that there was no objective evidence or published studies in humans that addressed interactions between hydrazine and the alleged incompatible medications to support Dr. Gold's contentions; 2) that unpublished animal data did not support the hypothesis that short-term use of tranquilizing agents with hydrazine would increase toxicity or decrease benefit; and 3) that at most, Russian animal data suggested that large doses of alcohol or barbiturates might increase toxicity (neither of which was used at these doses in any of the randomized trials). Dr. Mikhail Gershanovich, one of Russia's leading cancer specialists and a principal author of the Russian hydrazine studies (6), was interviewed and stated that he had no evidence of incompatibility between hydrazine and tranquilizers. The GAO report concluded that "subsequent analyses of patients' use of concurrent medications did not invalidate NCI conclusions that the drug [hydrazine] was ineffective."
One further point from the GAO report has not yet been published in the medical literature. In the NCTTG lung cancer trial (3), ondansetron, which does not interact with monoamine oxidase inhibitors, became available in early 1991 and was used in 91 patients, replacing benzodiazepines. Retrospective subset analysis of those patients in the hydrazine arm who received either ondansetron or benzodiazepines showed no statistically significant differences in survival time or time to disease progression between the two groups. Thus, even patients who received hydrazine without any of the medications objected to by Dr. Gold still did not show any benefit. My previous conclusion remains valid; namely, that there is considerable evidence that the use of the medications that Dr. Gold objects to were inconsequential in limiting the efficacy or increasing the toxicity of hydrazine.
BENTON M. WHEELER
